Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

GERMANTOWN, Md., Jun. 11 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop its [...]